Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQB3454 Tablet 'IDH1 Inhibitor'
10/07/2026 10:43
BRIEF-Sino Biopharmaceutical Says China's CDE Accepts NDA For TQB3454 Tablet 'IDH1 Inhibitor' July 10 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK:
CHINA'S CDE ACCEPTS NDA FOR TQB3454 TABLET 'IDH1 INHIBITOR' FOR ADVANCED BTC WITH IDH1 MUTATIONS
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit